Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): recruitment, retention, and data availability in a longitudinal remote measurement study.
Cohort study
Longitudinal
Major depressive disorder
Multicentre
Remote measurement technologies
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
21 02 2022
21 02 2022
Historique:
received:
11
06
2021
accepted:
02
02
2022
entrez:
22
2
2022
pubmed:
23
2
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Major Depressive Disorder (MDD) is prevalent, often chronic, and requires ongoing monitoring of symptoms to track response to treatment and identify early indicators of relapse. Remote Measurement Technologies (RMT) provide an opportunity to transform the measurement and management of MDD, via data collected from inbuilt smartphone sensors and wearable devices alongside app-based questionnaires and tasks. A key question for the field is the extent to which participants can adhere to research protocols and the completeness of data collected. We aimed to describe drop out and data completeness in a naturalistic multimodal longitudinal RMT study, in people with a history of recurrent MDD. We further aimed to determine whether those experiencing a depressive relapse at baseline contributed less complete data. Remote Assessment of Disease and Relapse - Major Depressive Disorder (RADAR-MDD) is a multi-centre, prospective observational cohort study conducted as part of the Remote Assessment of Disease and Relapse - Central Nervous System (RADAR-CNS) program. People with a history of MDD were provided with a wrist-worn wearable device, and smartphone apps designed to: a) collect data from smartphone sensors; and b) deliver questionnaires, speech tasks, and cognitive assessments. Participants were followed-up for a minimum of 11 months and maximum of 24 months. Individuals with a history of MDD (n = 623) were enrolled in the study,. We report 80% completion rates for primary outcome assessments across all follow-up timepoints. 79.8% of people participated for the maximum amount of time available and 20.2% withdrew prematurely. We found no evidence of an association between the severity of depression symptoms at baseline and the availability of data. In total, 110 participants had > 50% data available across all data types. RADAR-MDD is the largest multimodal RMT study in the field of mental health. Here, we have shown that collecting RMT data from a clinical population is feasible. We found comparable levels of data availability in active and passive forms of data collection, demonstrating that both are feasible in this patient group.
Sections du résumé
BACKGROUND
Major Depressive Disorder (MDD) is prevalent, often chronic, and requires ongoing monitoring of symptoms to track response to treatment and identify early indicators of relapse. Remote Measurement Technologies (RMT) provide an opportunity to transform the measurement and management of MDD, via data collected from inbuilt smartphone sensors and wearable devices alongside app-based questionnaires and tasks. A key question for the field is the extent to which participants can adhere to research protocols and the completeness of data collected. We aimed to describe drop out and data completeness in a naturalistic multimodal longitudinal RMT study, in people with a history of recurrent MDD. We further aimed to determine whether those experiencing a depressive relapse at baseline contributed less complete data.
METHODS
Remote Assessment of Disease and Relapse - Major Depressive Disorder (RADAR-MDD) is a multi-centre, prospective observational cohort study conducted as part of the Remote Assessment of Disease and Relapse - Central Nervous System (RADAR-CNS) program. People with a history of MDD were provided with a wrist-worn wearable device, and smartphone apps designed to: a) collect data from smartphone sensors; and b) deliver questionnaires, speech tasks, and cognitive assessments. Participants were followed-up for a minimum of 11 months and maximum of 24 months.
RESULTS
Individuals with a history of MDD (n = 623) were enrolled in the study,. We report 80% completion rates for primary outcome assessments across all follow-up timepoints. 79.8% of people participated for the maximum amount of time available and 20.2% withdrew prematurely. We found no evidence of an association between the severity of depression symptoms at baseline and the availability of data. In total, 110 participants had > 50% data available across all data types.
CONCLUSIONS
RADAR-MDD is the largest multimodal RMT study in the field of mental health. Here, we have shown that collecting RMT data from a clinical population is feasible. We found comparable levels of data availability in active and passive forms of data collection, demonstrating that both are feasible in this patient group.
Identifiants
pubmed: 35189842
doi: 10.1186/s12888-022-03753-1
pii: 10.1186/s12888-022-03753-1
pmc: PMC8860359
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2022. The Author(s).
Références
Obesity (Silver Spring). 2020 Dec;28(12):2272-2281
pubmed: 32845582
Br J Psychiatry Suppl. 2000;(39):s28-33
pubmed: 10945075
Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288
pubmed: 31823381
BMC Psychiatry. 2019 Feb 18;19(1):72
pubmed: 30777041
Health Serv Res. 2018 Jun;53(3):1407-1429
pubmed: 28480588
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Psychiatry Res. 2018 Nov;269:157-171
pubmed: 30149273
JMIR Mhealth Uhealth. 2019 Aug 01;7(8):e11734
pubmed: 31373275
J Med Internet Res. 2018 Jul 12;20(7):e10480
pubmed: 30001997
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Front Psychiatry. 2020 Dec 18;11:584711
pubmed: 33391050
J Med Internet Res. 2020 May 29;22(5):e17572
pubmed: 32348255
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
Neuropsychiatr Dis Treat. 2018 May 22;14:1339-1350
pubmed: 29872301
Psychol Med. 2009 Sep;39(9):1533-47
pubmed: 19215626
Alcohol Clin Exp Res. 2000 May;24(5):659-65
pubmed: 10832907
World Psychiatry. 2017 Jun;16(2):219-220
pubmed: 28498573
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
JMIR Mhealth Uhealth. 2019 Jan 30;7(1):e11325
pubmed: 30698535
J Biomed Inform. 2018 Jan;77:120-132
pubmed: 29248628
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Lancet Digit Health. 2020 Feb;2(2):e85-e93
pubmed: 33334565
NPJ Digit Med. 2022 Jan 11;5(1):3
pubmed: 35017634
Neuropsychiatr Dis Treat. 2018 Oct 29;14:2861-2877
pubmed: 30464471
J Psychosom Res. 2005 Jan;58(1):15-8
pubmed: 15771865
BMC Public Health. 2012 Oct 29;12:918
pubmed: 23107281
World Psychiatry. 2017 Oct;16(3):287-298
pubmed: 28941113
BMC Med. 2017 Dec 12;15(1):215
pubmed: 29228943
Behav Res Ther. 2019 Dec;123:103503
pubmed: 31715324
Psychol Med. 2004 Aug;34(6):1001-11
pubmed: 15554571
J Affect Disord. 2021 Jan 15;279:164-172
pubmed: 33059219
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
J Clin Psychiatry. 2010 Dec;71(12):1645-56
pubmed: 21190638
Int J Methods Psychiatr Res. 2014 Mar;23(1):36-48
pubmed: 24474683
J Med Internet Res. 2018 Jun 06;20(6):e199
pubmed: 29875089
Psychol Med. 2017 Jan;47(2):279-289
pubmed: 27702414
PLoS One. 2017 Aug 3;12(8):e0182162
pubmed: 28771530
J Affect Disord. 2019 Mar 1;246:763-774
pubmed: 30623822
Evid Based Ment Health. 2017 Nov;20(4):97
pubmed: 29056607
NPJ Digit Med. 2020 Mar 25;3:45
pubmed: 32219186
J Clin Psychiatry. 2017 Jul;78(7):873-881
pubmed: 28858441
JMIR Mhealth Uhealth. 2019 Jan 18;7(1):e11941
pubmed: 30664463
Acta Psychiatr Scand. 1990 Jul;82(1):77-81
pubmed: 2399824
J Med Internet Res. 2020 Sep 25;22(9):e19992
pubmed: 32877352
Can J Psychiatry. 2016 Feb;61(2):71-9
pubmed: 27253697
Eur J Epidemiol. 2004;19(8):751-60
pubmed: 15469032